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Background and PurposezzFew of the epidemiologic studies of epilepsy have utilized well-
validated nationwide databases. We estimated the nationwide prevalence of treated epilepsy 
based on a comprehensive medical payment database along with diagnostic validation.
MethodszzWe collected data on patients prescribed of antiepileptic drugs (AEDs) from the 
Health Insurance Review and Assessment service, which covers the entire population of Ko-
rea. To assess the diagnostic validity, a medical records survey was conducted involving 6,774 
patients prescribed AEDs from 43 institutions based on regional clusters and referral levels 
across the country. The prevalence of treated epilepsy was estimated by projecting the diag-
nostic validity on the number of patients prescribed AEDs.
ResultszzThe mean positive predictive value (PPV) for epilepsy was 0.810 for those prescribed 
AEDs with diagnostic codes that indicate epilepsy or seizure (Diagnosis-E), while it was 0.066 
for those without Diagnosis-E. The PPV tended to decrease with age in both groups, with lower 
values seen in females. The prevalence was 3.84 per 1,000, and it was higher among males, chil-
dren, and the elderly.
ConclusionszzThe prevalence of epilepsy in Korea was comparable to that in other East Asian 
countries. The diagnostic validity of administrative health data varies depending on the 
method of case ascertainment, age, and sex. The prescriptions of AEDs even without relevant 
diagnostic codes should be considered as a tracer for epilepsy.
Key Wordszz epilepsy, seizure, prevalence, health data, epidemiology, validation.
Estimating the Prevalence of Treated Epilepsy Using 
Administrative Health Data and Its Validity: 
ESSENCE Study
INTRODUCTION
Epilepsy is a common neurologic disorder, with a reported prevalence ranging from 2.2 
to 17.6 per 1,000.1 Until recently, epidemiologic reports on the prevalence of epilepsy in 
Korea were lacking. Previously the authors reported the prevalence of treated epilepsy based 
on the diagnostic codes for claims and the antiepileptic drugs (AEDs) prescribed, using 
the database from the National Health Insurance (NHI), public third party payment sys-
tem.2 That study found that the overall prevalence was 2.41 per 1,000, which is very near 
to the bottom of the range of the rates found in other countries. However, because the di-
agnostic codes of the NHI database were generated for claims, it is crucial to validate the 
accuracy of these codes. Although the use of administrative health data for epidemiologic 
studies has been increasing, few studies have estimated the prevalence adjusted by diagnos-
tic validity. The diagnostic validity may depend on demographic, institutional, or clinical 
variables, and applying validity that is specific for subgroups will allow more accurate esti-
mation of prevalence.
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In this study we aimed to estimate the age- and sex-specific 
prevalence of epilepsy with less bias, by using a nationwide 
database supplemented by extensive validation performed 
using a medical records survey of the representative sample.
METHODS
Study design
We conducted two surveys in parallel: 1) a Health Insurance 
Review and Assessment service (HIRA) database survey and 
2) a medical records survey. Data on potential epilepsy patients 
were extracted from the main HIRA database based on our 
working criteria described below. We also performed a nation-
wide survey of medical records of patients sampled from rep-
resentative health institutes. Using the results of the medical 
records survey, we assessed positive predictive value (PPV), 
the probability of the HIRA database patients having epilepsy, 
according to diagnostic codes, age group, and sex. Finally, we 
estimated the prevalence of treated epilepsy by projecting the 
PPV derived from the medical records survey involving the 
number of initially presumed epilepsy patients from the HIRA 
database after stratifying for covariates (Fig. 1).
This study was approved by the Institutional Review Board 
(IRB) of the lead institutes (approval number: AN10221-001) 
and all participating institutes with an IRB.
Data sources 
The national health system of Republic of Korea is based on 
the NHI system, registration in which is mandatory for the 
entire population and for all medical facilities, and Medicaid 
(MA), which is provided through a social welfare fund for 
registrants who are unable to pay the NHI premiums. The 
population coverage has been greater than 98% since 2005.3 
This is basically a fee-for-service system, and all medical ex-
penditures including for medications, medical services, and 
revenue are submitted to HIRA as separate claims. HIRA is 
a governmental third-party agency that has assessed all claims 
based on diagnostic codes and medical records from NHI 
HIRA database survey 
(entire population, n=50,290,771)
Sort by person
(n=1,119,360)
Number of epilepsy patients
(n=126,595)
Number of epilepsy patients
(n=60,902)
Extraction of the data of the 
patients who received AEDs
(n=7,282,236)
Estimated total number 
of epilepsy patients
(n=187,497)
Cases prescribed of AEDs and 
with diagnostic code
(n=2,374)
Cases prescribed of AEDs and 
without diagnostic code
(n=4,400)
Health resource utilization database
Medical record survey 
(stratified sample, n=6,774)
Fig. 1. Study design. AEDs: antiepileptic drugs, HIRA: Health Insurance Review and Assessment service.
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and MA since 2000, and from the Veterans Administration 
since 2008. Costs for virtually all diagnostic and therapeutic 
practices associated with epilepsy are covered by the system, 
and all related records are stored in the HIRA database. We 
excluded patients under 1 year of age because we found that 
it is often difficult to determine from reviews of medical re-
cords whether they have epilepsy or acute symptomatic sei-
zures at this age.
Potential patient dataset using the HIRA database 
Our working criterion for extracting potential patients with 
epilepsy from the HIRA database was a prescription for at 
least one AED according to the list of claims in 2009. The 
list of AEDs, based on those available in 2009 in Korea, in-
cluded carbamazepine, clobazam, ethosuximide, gabapen-
tin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbi-
tal, phenytoin, pregabalin, primidone, topiramate, vigabatrin, 
valproate, and zonisamide. Clonazepam was excluded be-
cause it is rarely used as a monotherapy for epilepsy and is 
used more frequently in other conditions. Other AEDs, in-
cluding primidone, felbamate, esclicarbazepine, lacosamide, 
and tiagabine, were not available in 2009.
Potential epilepsy patients were classified into two cate-
gories: those prescribed AEDs with and without diagnostic 
codes indicating epilepsy or seizure (Diagnosis-E), based on 
either the principal or additional diagnostic code for the claim. 
Diagnosis-E included G40* (epilepsy), G41* (status epilepti-
cus), F803 (Landau-Kleffner syndrome), and R56 (convulsion) 
according to the 10th version of the International Classifi-
cation of Diseases and Related Health Problems (ICD-10).
In total, 7,282,236 claims from patients prescribed AEDs 
during 2009 were retrieved. The claims were sorted by indi-
vidual based on anonymous personal identifiers and hospital 
identifiers, in order to determine the actual number of pa-
tients for 2009 (Fig. 1).
Medical records survey and validation of diagnostic 
codes for epilepsy
We collected clinical information on epilepsy patients by sur-
veying the medical records for the validation of diagnostic 
codes. The survey consisted of two steps: 1) data abstraction 
by certified health record administrators and 2) subsequent 
verification by epileptologists. The health record administra-
tors were trained to review medical records and extract data 
related to epilepsy. All cases were scrutinized and assessed by 
a board of epileptologists based on detailed clinical informa-
tion abstracted by the health record administrators. Diagno-
ses were categorized as follows based on the 1993 Interna-
tional League Against Epilepsy guidelines: epilepsy, single 
seizure, uncertain whether epilepsy or seizure, nonepileptic, 
and undetermined.4 This survey method demonstrated a high 
validity in a preliminary study, with a sensitivity of 90% and a 
specificity of 97%, and kappa statistics for interrater and test-
retest reliabilities of 0.907 and 0.975, respectively.5
Multistage cluster sampling was performed in three geo-
graphic regions (the capital, midland, and southeast areas) 
categorized based on approximately even distributions of 
institutes and population. Based on a pilot survey of three hos-
pitals, the sample size was estimated at 2,000 for patients 
prescribed AEDs with Diagnosis-E, and 4,000 for those pre-
scribed without Diagnosis-E. Finally, we surveyed 6,774 pa-
tients from 43 institutes distributed throughout the country, 
comprising 4 tertiary referral hospitals, 29 general hospi-
tals, 8 hospitals, and 2 private clinics.
Estimation of prevalence 
The PPV for epilepsy was calculated as the number of patients 
with true epilepsy divided by the total number of patients 
prescribed AEDs, for age, sex, and diagnostic categories.
The total number of the cases was estimated as
N=NDi×PDi+NMi×PMi,
where PDi=       , PMi=       ,EDiDi
EMi
Mi
NDi is the number of patients prescribed AEDs with Diagno-
sis-E according to the HIRA claims data, NMi is the number of 
patients prescribed AEDs without Diagnosis-E according to 
the HIRA claims data, PDi is the PPV for patients prescribed 
AEDs with Diagnosis-E, PMi is the PPV for patients prescribed 
AEDs without Diagnosis-E, Di is the number of patients pre-
scribed AEDs with Diagnosis-E, Mi is the number of patients 
prescribed AEDs without Diagnosis-E, EDi is the number of 
cases deemed to be true epilepsy among Di, and EMi is the 
number of cases deemed to be true epilepsy among Mi, based 
on the medical records survey.
We applied the PPV derived from the medical records sur-
vey to groups of subjects extracted from the HIRA database 
according to specific strata. We used the age- and sex-specific 
national population estimated for 2009 from the Korean na-
tional statistical office as the denominator when calculating 
the prevalence.6
RESULTS
Validity of diagnostic codes
Among the total of 50,290,771 beneficiaries, 1,119,360 pa-
tients (2.2%) were prescribed AEDs during 2009, of which 
155,307 (13.9%) had Diagnosis-E and 964,053 (86.1%) did 
not have Diagnosis-E. The PPV for epilepsy was 0.460–0.978 
(overall 0.810) for the group with Diagnosis-E and 0.021–
0.324 (overall 0.066) for the group without Diagnosis-E. The 
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ranges indicate the variations with age and sex: the PPV 
tended to decrease with age in both groups, with consistent-
ly lower values in females over 30 years of age based on the 
medical records survey (Table 1).
The number of patients prescribed AEDs with Diagnosis-E 
but deemed not to have epilepsy was estimated at 28,712 na-
tionwide. The false-positive cases were determined to be acute 
symptomatic seizures, single seizure, or uncertain whether 
epilepsy or seizure (41.9%); therapeutic trial for possible sei-
zures (7.07%); prophylactic use (18.2%); misassignment of 
the diagnostic codes for pain (23.7%); other purpose (4.29%); 
or due to an unknown cause (4.80%).
The number of patients prescribed AEDs without Diagno-
sis-E but determined as having epilepsy was estimated at 
60,902 nationwide. The false-negative cases had diagnostic 
codes suggesting central nervous system pathology poten-
tially related to epilepsy (53.6%); psychiatric illness (5%); 
paroxysmal disorders requiring differentiation from epilepsy, 
such as syncope, dystonia, cramps, and headache (5%); and 
those unrelated to epilepsy (36.4%).
Prevalence
The estimated number of epilepsy patients treated with AEDs 
was 187,497 [95% confidence interval (CI)=185,512–188,697]. 
The overall prevalence was 3.84 per 1,000 (95% CI=3.81–
3.87). The prevalence was higher in males (4.20 per 1,000; 
95% CI=4.17–4.23) than in females (3.47 per 1,000; 95% 
CI=3.44–3.51) for all age groups except patients aged 1–9 
years (males: 4.57 per 1,000; females: 5.78 per 1,000). The 
prevalence was relatively constant across age groups, with a 
tendency to be higher in patients younger than 15 years and 
in the elderly (Fig. 2) (Supplementary Table 1 in the online-
only Data Supplement).
The prevalence of treated epilepsy with Diagnosis-E was 
2.59 per 1,000 (males: 2.94 per 1,000; females: 2.32 per 
1,000), and the prevalence of those without Diagnosis-E was 
1.25 per 1,000 (males: 1.26 per 1,000; females: 1.23 per 1,000). 
Age- and sex-specific prevalence patterns differed between 
groups with and without Diagnosis-E. A plot of the preva-
lence against age had an inverted U-shape peaking at adoles-
cence for patients with Diagnosis-E, and an upright U-shape 
for the group without Diagnosis-E (Fig. 3).
Table 1. Positive predictive values for epilepsy in patients prescribed antiepileptic drugs according to diagnostic code category, age, and sex, based 
on a medical records survey (n=6,774)
Age, years
With diagnostic code indicating epilepsy 
or seizure (n=2,374)
Without diagnostic code indicating epilepsy 
or seizure (n=4,400)
Males Females Total Males Females Total
1–4 0.857 0.833 0.847 0.246 0.324 0.276
5–9 0.936 0.923 0.929 0.237 0.298 0.264
10–14 0.940 0.925 0.933 0.234 0.205 0.220
15–19 0.978 0.897 0.944 0.125 0.150 0.136
20–29 0.897 0.943 0.918 0.211 0.143 0.178
30–39 0.897 0.852 0.877 0.142 0.092 0.118
40–49 0.877 0.840 0.861 0.092 0.050 0.070
50–59 0.784 0.692 0.747 0.061 0.024 0.040
60–69 0.633 0.556 0.603 0.023 0.023 0.023
≥70 0.536 0.460 0.500 0.042 0.023 0.031
≥65 0.562 0.505 0.535 0.035 0.021 0.027
Total 0.825 0.790 0.810 0.084 0.052 0.066* 
*p<0.001 for analysis of variance between males and females without diagnostic codes.
Fig. 2. Prevalence of treated epilepsy according to age group and 
sex. The prevalence was higher in males than in females for all age 
groups except patients aged 1–9 years. The prevalence was relatively 
constant across age groups, although with a tendency to be higher 
in patients younger than 15 years of age and the elderly.
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DISCUSSION
This study determined the nationwide prevalence of treated 
epilepsy across all ages except infants utilizing a nationwide 
database and validated by a medical records survey. Only a few 
studies have estimated the prevalence of epilepsy for the entire 
population of a country, for which various data sources can be 
used. A door-to-door survey is a traditional gold standard, but 
it is not practical in a large population. Although a population-
level self-report survey has less selection bias and is less de-
manding than a door-to-door survey, its diagnostic accuracy is 
uncertain. A records-based survey is advantageous over a di-
rect population survey in that it avoids recall bias, although se-
lection bias may be an issue. In countries with universal health 
care systems, the utilization of administrative health databases 
is useful for nationwide epidemiologic studies with a relatively 
low selection bias.7-9
The main concerns when using administrative health data 
for epilepsy epidemiology studies are the correct identifica-
tion of epilepsy cases and the determination of their validi-
ty. Diagnostic codes are commonly used as tracers for epi-
lepsy8,10 and are often combined with AED prescriptions.7,9,11 
The validity of ICD codes for epilepsy or seizure in admin-
istrative health data has reported to be associated with PPV 
values of 0.347–1.00 and negative predictive values (NPVs) 
of 0.895–0.997.12,13 The overall PPV and NPV of ICD codes 
for epilepsy or seizure in the HIRA database were 0.810 and 
0.934, which are comparable to those of other studies, al-
though we included only patients who had been prescribed 
AEDs. Case-defining algorithms that also take into account 
the duration of AED use, electroencephalogram, hospital-
ization, or emergency-room visits, and/or the number of 
billings could increase the validity, but there is a trade-off 
between the false-positive and false-negative rates.13-15 The 
validity of the diagnostic codes has been assessed by a medi-
cal records review in several studies,10,12,14-16 by reports from 
general practitioners in an Italian study,13 and by a commu-
nity-based survey in a Taiwanese study.9 We traced epilepsy 
patients based on AED prescriptions, and assessed their PPV 
based on a review of medical records. The PPV decreased 
with age and was lower among female patients with or with-
out Diagnosis-E, which may be due to the use of AEDs for 
nonepileptic purposes being more common in these popu-
lations. It is remarkable that 6.61% of the patients prescribed 
AEDs without Diagnosis-E were deemed to have epilepsy. 
Although the rate of false-negative diagnoses was relatively 
low, this group of patients constituted 32.6% of all treated 
epilepsy patients and was more than twice the number of 
false-positive diagnoses. Many studies of epilepsy prevalence 
using administrative databases,8,10,11,17 including our previ-
ous study,2 did not consider patients prescribed AEDs with-
out Diagnosis-E as potential epilepsy patients, which may 
have resulted in the prevalence being underestimated. 
The overall prevalence in this study is within the range re-
ported for other East Asian countries (2.9 per 1,000 and 5.9 
per 1,000).9,18,19 We found a male predominance, which is 
also consistent with most of the previous studies conducted 
in Asia, Europe, and North America.1,8,9,20 The prevalence in-
creased with age in males, whereas it remained constant in 
females; this may be explained by a greater incidence of trau-
ma and stroke—which are the leading causes of epilepsy—in 
males.21
The prevalence varied with age as a gentle U-shaped curve, 
with the prevalence being higher in children and the elder-
ly. This pattern may reflect the remission of a considerable 
proportion of childhood epilepsies at adolescence22 and the 
increase in various brain pathologies with age. The preva-
lence was highest among young patients with Diagnosis-E, 
whereas the prevalence was U-shaped in patients without 
Diagnosis-E, which suggests that Diagnosis-E was assigned 
less frequently to elderly and pediatric patients with epilepsy. 
This is perhaps because symptomatic epilepsy is more com-
mon in these populations, particularly in elderly individuals, 
and only diagnostic codes for the primary underlying con-
dition, such as stroke, head trauma, or neurodegenerative 
disease, were entered into the system. Physicians may defer 
coding epilepsy or seizure in children due to the social stig-
matization and negative attitudes toward epilepsy.23
Our study was subject to several limitations. Because we 
used the HIRA database, and thus included only patients ac-
tively seeking medical attention, we were able to estimate 
Fig. 3. Age- and sex-specific prevalence of treated epilepsy in pa-
tients with and without diagnostic codes indicating epilepsy or sei-
zure (Diagnosis-E). The curves appeared as an inverted U-shape peak-
ing at adolescence for patients with Diagnosis-E, and as an upright 
U-shape for the group without Diagnosis-E. M: males, F: females.
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the prevalence of treated epilepsy but not that of all epilepsy 
cases. This may have resulted in underestimation of the ac-
tual prevalence of epilepsy in Korea, although the treatment 
gap is anticipated to be minimal because of the high acces-
sibility to health institutions and the 70–100% coverage of 
costs for AEDs in Korea. Another overlooked group was pa-
tients who used AEDs that were not recorded in the HIRA 
database; for example, patients who covered the costs them-
selves to avoid stigma and those who were reimbursed by 
means other than NHI, such as automobile insurance or in-
dustrial accident compensation. Our medical records sur-
vey was performed only at institutes that agreed to join the 
study, which could result in a selection bias in the estimation 
of diagnostic validity. In spite of these limitations, our study 
had strengths in that it was performed nationwide and cov-
ered the entire population, and the prevalence was estimated 
by diagnostic validation according to strata based on an ex-
tensive survey of medical records.
Conclusions
We have estimated the nationwide prevalence of epilepsy us-
ing claims data from administrative health database com-
plemented by a medical records survey. We were able to cal-
culate reliable age- and sex-specific prevalence, by applying 
stratified diagnostic validity from a medical records survey 
of a large number of samples. The overall prevalence was 
comparable to those found in other East Asian countries. 
The age-specific prevalence appeared as a U-shaped graph, 
being higher among the young and the elderly. Administra-
tive health data may reveal variability in diagnostic validity 
according to the method of case ascertainment, age, and sex, 
and a significant number of treated patients with epilepsy 
may not show diagnostic codes for epilepsy or seizure. Our 
study may provide a basis for further epidemiologic studies 
using administrative health databases.
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